Objective: Immunological abnormalities play a role in the pathophysiology of mania and have been associated with relapse. Probiotic organisms such as Lactobacilli and Bifidobacteria modulate inflammation in humans and animal models. The trial examined whether the administration of probiotic organisms prevents psychiatric rehospitalizations in patients recently discharged following hospitalization for mania.
| INTRODUC TI ON
Individuals who are hospitalized for mania are at high risk for the recurrence of mood episodes and for psychiatric rehospitalization in the months after hospital discharge. 1, 2 Data from recent observational studies indicate that rehospitalization is common in this population even when evidence-based treatments are used. 2, 3 Immunological abnormalities have been identified in individuals with mania and may contribute to the pathophysiology of this acute mood state as well as to bipolar disorder more broadly. [4] [5] [6] [7] In a previous study performed by our group, individuals hospitalized for mania with increased levels of inflammation were more likely to be rehospitalized in the 6 months following discharge. 8 In these studies, the levels of inflammation were determined by factor analysis of the levels of class-specific antibodies to auto-antigens, food-derived antigens, and infectious agents. Specific antigens employed in the calculation were the NR2 peptide of the N-methyl-D-aspartate (NMDA) receptor; wheat gliadin; the Mason-Pfizer monkey virus protein p24, and the protozoan Toxoplasma gondii. 9 These findings provide the rationale for a study of immune modulatory agents as a strategy to prevent rehospitalization in patients who have been hospitalized recently for mania. Probiotic microorganisms are non-pathogenic anaerobic bacteria such as Lactobacilli and Bifidobacteria which are found in breast milk and in some fermented food products. Probiotic microorganisms have been shown to modulate the immune response in humans [10] [11] [12] and experimental animals. 13, 14 These organisms have been found to have positive health effects for some gastrointestinal disorders and other health conditions. [15] [16] [17] [18] [19] [20] There is increasing evidence for the potential benefits of probiotic microorganisms to alleviate mood symptoms. [21] [22] [23] [24] The effect is presumed to be based on the anti-inflammatory and immune regulatory effect of probiotics on gastrointestinal inflammation which modulates mood through the gut-brain axis. 25 However, most of the trials that have been performed have examined mood symptoms in individuals with relatively mild mood symptoms. There have not been any published trials in mania.
Based on these considerations, we undertook a placebocontrolled double-blind study to determine whether the administration of probiotic microorganisms as adjunctive treatment added to standard psychiatric medications could prevent psychiatric rehospitalizations in individuals who had recently been discharged following hospitalization for mania.
| ME THODS

| Participants
Participants were recruited from inpatient and day hospital programs at the Sheppard Pratt Health System, a large not-for-profit psychiatric health system in Baltimore, Maryland. Inclusion crite- 
| Procedures
Patients were recruited during the time when they were admitted to the inpatient or day hospital programs for symptoms of a manic episode and participated in the study within the period 27 November 2012 to 28 December 2016. All participants provided written informed consent following an explanation of the study rationale and procedures. The study was approved by the Sheppard Pratt
Institutional Review Board. The trial was overseen by a Data Safety
Monitoring Board which reviewed the adverse event data at regular intervals during the trial.
The double-blind randomization period started after the participant had been discharged from the acute hospital stay. Assignment was 1:1 to each treatment condition with a parallel two-group design. Block randomization was performed based on the Young Mania Rating Scale (YMRS) 27 score which was assessed at the initial study visit based on whether the score was above or below the median YMRS score calculated from previous observational data. 8 The block randomization was performed in blocks of four and assignment made with a computer random number generator. Participants, investigators, and clinical research staff were masked as to the participants' study condition.
At week 0, the start of the randomized phase, symptom assessments were performed including the YMRS, 27 Montgomery-Åsberg Depression Rating Scale (MADRS), 28 and Brief Psychiatric Rating Scale (BPRS).
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The double-blind treatment phase lasted from week 0 through week 24. After randomization at week 0, the participant was evaluated at in-person visits every 4 weeks at weeks 4, 8, 12, 16, 20, and 24, at which time symptom evaluations were repeated. At these evaluations, participants were also assessed for compliance with the study medication by pill counts, current psychiatric and somatic medications, and any adverse events. Participants were contacted by telephone each week between in-person study visits to promote adherence to the study, and to inquire about any adverse events and emergent mood symptoms. All participants were instructed to continue with their regularly prescribed medications and other psychiatric treatments during the trial.
Blood samples were collected when patients were screened at baseline. These samples were used to calculate an inflammation score as previously described 8 protein were generated by imputation employing multivariate normal regression. 30 The score was calculated based on principal components factors derived from the antibody levels measured in 377 control individuals without a psychiatric disorder selected as previously described. 31 The inflammation score was expressed both as a continuous variable and as a value ≥10th, ≥25th, and ≥50th percentiles of the values measured in the control population.
Data about psychiatric inpatient rehospitalizations were obtained from participant self-report at each study visit in response to standardized questions and then verified from medical records.
Following randomization, a readmission within 3 days of a hospital discharge was counted as a single rehospitalization event.
| Study compound
Participants were randomized to receive daily a tablet containing
Lactobacillus GG and Bifidobacterium lactis strain Bb12 (>10 8 colonyforming units) in maltodextrin and microcrystalline cellulose or identical-appearing placebo containing just maltodextrin and microcrystalline cellulose for the 24-week randomized phase. The probiotic product was obtained from Chr. Hansen (Horsholm, Denmark).
The study compound was refrigerated and stored in aluminum tubes to maintain stability. At each in-person visit, participants received 1 month of the supplement which was then stored at room temperature. Participants were instructed to take the study drug daily with a meal or snack.
| Statistical analyses
The primary outcome was the time to psychiatric inpatient rehos- All statistical analyses were performed with stata version 11
(StataCorp, College Station, TX, USA).
The CONSORT checklist is included as Table S1 .
| RE SULTS
As shown in the CONSORT diagram in Figure 1 , a total of 83 patients provided signed consent and completed the baseline visit which was begun when they were hospitalized for acute mania; of these, 17 terminated their participation before randomization, the reasons for which are presented in the diagram. A total of 66 patients were thus randomized, of whom 52 (79%) completed the full 24 weeks of the trial. The early terminators were divided equally between the probiotic and placebo groups. The characteristics of the 66 randomized participants are depicted in Table 1 .
The probiotic and placebo groups did not differ significantly on any demographic, clinical, or medication variable at the start of the trial.
A total of 17 (51.5%) of the 33 participants in the placebo group had at least one rehospitalization during the study period. In contrast, only eight (24.2%) of the individuals receiving probiotics had a rehospitalization (χ 2 = 5.2, P = .022). All of the rehospitalizations were due to worsening psychiatric symptoms. A detailed description of the psychiatric rehospitalizations is presented in Table S2 . There were a total of 32 psychiatric rehospitalizations, 24 in the placebo group and eight in the probiotic group (z = 2.63, P = .009 adjusted for age, gender, race, and multiple hospitalizations per individual).
There were three individuals in the placebo group hospitalized more than once, with rehospitalizations occurring two, three and five times, respectively. Overall, individuals in the placebo group were rehospitalized for a mean of 8. ANOVA by week, P > .1). There were no significant differences between the placebo and probiotic groups at any study visit (week × treatment, all P > .1).
| Safety and side effects
The study medication was well tolerated by study participants and there were no withdrawals from the study due to complaints about the study medication. There were no other serious adverse events beyond those reported for psychiatric rehospitalization, except for one medical hospitalization of a participant in the probiotic group who was hospitalized for 2 days after a fall. Somatic adverse events reported by study participants are presented in Table 2 . There were no significant differences between groups in the number of participants who experienced somatic adverse events overall or by any body system (all P > .1, chi-square or Fisher's exact test).
| D ISCUSS I ON
This placebo-controlled double-blind study documented that the adjunctive administration of the probiotic organisms Lactobacillus Other 7 7 a Differences between groups all P > .05.
probiotic treatment was increased in individuals with elevated levels of systemic inflammation as measured by a previously described inflammation score. Probiotic treatment in the group of individuals with levels of inflammation ≥ the 50th percentile of a control group was associated with hazard ratios of 0.09, in terms of both first rehospitalization and all rehospitalizations during the study period.
These findings indicate that for individuals with relatively high rates of systemic inflammation adjunctive probiotic treatment was associated with an approximately 90% reduction in risk of rehospitalization during the study period.
The principle of probiotic therapy is based on the fact that systemic inflammation is dependent to some extent on gastrointesti- Bifidobacteria. 34 Since few adults living in the USA have intestinal flora that contain predominantly Lactobacilli or Bifidobacteria, probiotic therapies have been devised which attempt to alter intestinal flora by the feeding of these organisms. [35] [36] [37] Although the specific mechanisms by which probiotic microorganisms achieve their beneficial effects are not known with certainty, it is likely that they alter the balance of the gut microbiota and modulate the immune response to both external and self-derived antigens. as bipolar depression and major depression. 39 The possible role of adjunctive probiotics in the management of these and other psychiatric disorders should also be the subject of future studies.
We focused our study on individuals recently discharged following hospitalization for acute mania, since we and others had previously identified these individuals at a high risk for relapse as evidenced by rehospitalization. Even when compliance and the use of evidence-based treatments are assured, the risk of symptom exacerbations leading to rehospitalization remains relatively high. 2, 3 Recurrent mood episodes contribute to patients' social disability and reduce their quality of life. 40 Hospital readmissions in particular are disruptive to patients' lives and contribute to increased health care costs for patients and health care insurers. 41 Interventions that can address this outcome are thus a high priority.
It is of note that, while we found a significant difference between treatment groups in terms of the primary outcome of rehospitalization, we did not find a difference in mean levels of psychiatric symptom measures that were assessed at monthly study visits. One likely explanation is that symptoms assessed at widely spaced study visits do not necessarily capture the most severe symptom episodes such as those leading to hospital admission. A life chart mood rating system, in which symptoms are rated more frequently, would better determine changes in symptoms associated with the probiotic treatment.
There have been few controlled trials of probiotics in individuals with psychiatric disorders. Akkasheh et al. found an effect on depression scores in an 8-week trial of outpatients with major depressive disorder. 42 Romijn et al. found no effect on depression in individuals with mild symptoms also in an 8-week trial. 43 Our trial differed from these studies in that we focused on patients with acute mania receiving hospital-level care prior to study entry. Our current trial also contrasts with a recent study in which a similar probiotic preparation did not alter symptoms in individuals with established schizophrenia. 44 The reasons for the differences in efficacy may be related to the outcome measures employed and the greater efficacy of probiotics in preventing a symptom exacerbation leading to hospital readmission as compared to reducing residual psychiatric symptoms in relatively stable outpatients. It is also possible that the inflammatory response differs in individuals with schizophrenia and mania. Additional studies in both populations employing differing treatment regimens and timing will be required to answer this question. It is of note that in the current study adjunctive probiotic therapy was initiated after hospital discharge, since it was deemed more feasible than instituting therapy during the initial hospital stay.
Future studies might achieve greater efficacy by initiating therapy prior to hospital discharge.
The relative safety, tolerability and low expense of probiotic regimens should facilitate these types of studies. It is of note in this regard that the probiotic compound we used is commercially available in Europe but is not commercially available in the USA. Products containing Lactobacillus GG and Bifidobacterium lactis are available commercially in the USA. However, care is required in determining equivalence in terms of the quantity and viability of the microorganisms in different preparations.
Our study had a number of strengths, including a randomized double-blind design and the employment of a specific objective outcome. We also had a high rate of retention after randomization despite the psychiatric acuity of the patient population. Our study had several limitations. (i) The treatment that patients received after hospital discharge was not standardized. Their medication treatments were individualized by the participants' providers and participants were on a variety of treatment regimens. It is of note that the groups did not differ significantly in terms of medications or symptom scores at the start of the trial.
(ii) The attrition in the sample between hospital discharge and the time of randomization suggests that our sample may not have been fully representative of patients hospitalized for mania. (iii) As noted above, we did not directly measure the effect of probiotics on the intestinal microbiome.
We also did not measure inflammation within the central nervous system through imaging techniques or the analysis of cerebrospinal fluid so as not to make the study unattractive to participants. The study of these measures in conjunction with probiotic treatment is an important goal of future studies.
In conclusion, the adjunctive administration of a probiotic preparation containing defined levels of Lactobacillus GG and
Bifidobacterium lactis strain Bb12 resulted in a significant reduction in the rate of psychiatric rehospitalization in individuals recently discharged following hospitalization for mania. The probiotic compound was well tolerated and had low levels of side effects. The adjunctive use of probiotics might represent a major addition to the therapeutic armamentarium for the management of mania and other mood disorders.
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